Overview
| Product name | Recombinant Human TGFR-1/ALK-5 Protein |
|---|
| Catalog No. | RP01408 |
|---|
| Description | Recombinant Human TGFR-1/ALK-5 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Met1-Glu125) of human TGFBR1/ALK5 (Accession #NP_004603.1) fused with a Fc, 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Human TGF-beta Protein at 2 μg/mL (100 μL/well) can bind TGFBR1 with a linear range of 3.9-80.49 ng/mL.
|
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | <1EU/μg |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
|---|
| Species | Human |
|---|
| Calculated MW | 39.90 kDa |
|---|
Background
Transforming growth factor, beta receptor I, also known as Transforming growth factor-beta receptor type I , Serine / threonine-protein kinase receptor R4, Activin receptor-like kinase 5, SKR4, ALK-5, and TGFBR1, is a single-pass type I membrane protein that belongs to the protein kinase superfamily and TGFB receptor subfamily. TGFBR1 / ALK-5 is found in all tissues examined. It is most abundant in placenta and least abundant in brain and heart. TGF-beta functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. Administration of TGF-beta is able to protect against mammary tumor development in transgenic mouse models in vivo. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers, with the majority of colon and gastric cancers being caused by an inactivating mutation of TGF-beta RII. On ligand binding, TGFBR1 / ALK-5 forms a receptor complex consisting of two type I I and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which auto-phosphorylate, then bind and activate SMAD transcriptional regulators.
Product information
| Synonym | TGFBR1; AAT5; ACVRLK4; ALK-5; ALK5; ESS1; LDS1; LDS1A; LDS2A; MSSE; SKR4; TGFR-1; tbetaR-I; TBRI; TBR-i |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-hFc&His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
